Login to Your Account

Biocryst files NDA for previously failed flu drug peramivir

By Catherine Shaffer
Staff Writer

Friday, December 20, 2013
Biocryst Pharmaceuticals Inc. has snatched victory from the jaws of defeat with a new drug application (NDA) filing for intravenous perimavir, a drug that failed a Phase III influenza trial just over a year ago.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription